Serum levels of growth hormone binding protein in children with normal and precocious puberty: relation to age, gender, body composition and gonadal steroids.
OBJECTIVE
To study the regulation of GHBP serum levels by gonadal steroids in normal and precocious puberty.


METHODS
We studied GHBP levels in relation to age, sex, pubertal maturation, body composition as well as to circulating IGF-I and gonadal steroid levels in 320 healthy children. Furthermore, we studied the regulation of circulating GHBP in 33 girls with central precocious puberty before and during gonadal suppression with GnRH agonist.


METHODS
GHBP was determined by a time-resolved fluoroimmunoassay (GHBP TR-FIA) based on a commercially available immunoassay for GH, the DELFIA GH assay.


RESULTS
In healthy children GHBP levels were significantly higher in normal girls compared with boys, and there was no significant increase in GHBP in puberty in both sexes. GHBP levels did not correlate with height (SDS), age, pubertal stage, IGF-I or testosterone/oestradiol levels in boys and girls, respectively. There were significant correlations between BMI and GHBP in boys and girls (R 2 = 0.14 and R 2 = 0.12, both P < 0.0001). Furthermore, GHBP correlated highly significantly with the percentage body fat, determined by BIA in 43 healthy girls (R 2 = 0. 40, P < 0.0001). GHBP levels were significantly higher in girls with central precocious puberty (CPP) (1.31 SDS (1.26), mean (SD)) compared to prepubertal controls (P < 0.0001), and above + 2 SD in 10 out of 33 patients. In girls with CPP, GHBP correlated inversely with oestradiol before treatment (R 2 = 0.26, P < 0.01) and there was a tendency towards a positive correlation with BMI (R 2 = 0.13, P = 0.078). By contrast, there were no signficant correlations between GHBP and IGF-I or height SDS. Gonadal suppression with GnRH agonist treatment caused a transient significant increase of 0.57 SD after 2 months of treatment (P < 0.001), but decreased to baseline levels hereafter.


CONCLUSIONS
We conclude that in children, as in adults, body fat is the primary determinant for the circulating level of GHBP, and that the difference in body fat is probably the main factor for the higher levels of serum GHBP in girls compared with boys, as well as for the negative influence of testosterone levels in boys and of oestrogen levels in girls. The elevation in GHBP levels observed in girls with central precocious puberty is probably due their higher body fat content.
Juul
A
A
Department of Growth and Reproduction GR, National University Hospital, University of Copenhagen, Denmark.
Fisker
S
S
Scheike
T
T
Hertel
T
T
Müller
J
J
Orskov
H
H
Skakkebaek
N E
NE
D000293:Adolescent; D000367:Age Factors; D000704:Analysis of Variance; D001823:Body Composition; D015992:Body Mass Index; D002064:Buserelin / Q000627:therapeutic use; D002352:Carrier Proteins / Q000097:blood*; D016022:Case-Control Studies; D002648:Child; D004958:Estradiol / Q000097:blood; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D016014:Linear Models; D008297:Male; D011629:Puberty, Precocious / Q000097:blood* / Q000188:drug therapy / Q000378:metabolism; D012737:Sex Factors; D013739:Testosterone / Q000097:blood
D002352:Carrier Proteins; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D004958:Estradiol; D007334:Insulin-Like Growth Factor I; D002064:Buserelin; C051815:somatotropin-binding protein